Announced details
Esophageal cancer for which curative resection and chemoradiotherapy are not indicated
10% pioneering development premium, 10% orphan drug premium and 10% utility premium
Sales partner. Sales are scheduled to be conducted through FUJIFILM Toyama Chemical.
Calculated National Health Insurance price: ¥3,102,489 (¥9,307,467 per patient)
The impact on the Company's financial results is currently under review
The company does not address Contract Value.
General Meeting of the Central Social Insurance Medical Council
| Item | Details |
|---|---|
| Names of Products / Services Covered | Telomelysin Injection (generic name: suratadenoturev; development code: OBP-301) |
| Counterparty | FUJIFILM Toyama Chemical Co., Ltd. |
| Relationship with the Company | Sales partner. Sales are scheduled to be conducted through FUJIFILM Toyama Chemical. |
| Offering price | Calculated National Health Insurance price: ¥3,102,489 (¥9,307,467 per patient) |
| Launch date | Sales scheduled to begin in the fiscal year ending December 2026 |
| Applicable area | Esophageal cancer for which curative resection and chemoradiotherapy are not indicated |
| Quantitative Effects | 10% pioneering development premium, 10% orphan drug premium and 10% utility premium |
| Impact on Business Performance | The impact on the Company's financial results is currently under review |
| Source | General Meeting of the Central Social Insurance Medical Council |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The proposed NHI reimbursement price was calculated using the comparator drug pricing method, with a 10% premium for pioneering development, a 10% orphan drug premium and a 10% utility premium applied.